Status:
COMPLETED
Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
Lead Sponsor:
Wills Eye
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
Detailed Description
To investigate the efficacy of needle bleb revisions with mitomycin C with subconjunctival bevacizumab in promoting both filtering success and favorable bleb morphologic features.
Eligibility Criteria
Inclusion
- require glaucoma bleb needle revision with Mitomycin-C
Exclusion
- pregnant, nursing, or not using adequate contraception
- other glaucoma eye surgery involving tube shunts
- prior retinal detachments surgery with scleral buckle
- infection, inflammation, or any abnormality preventing eye pressure measurement
- enrolled in another investigational study
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00853073
Start Date
February 1 2009
End Date
January 1 2012
Last Update
July 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wills Eye Institute, Glaucoma Service
Philadelphia, Pennsylvania, United States, 19107